Autologous Bone Marrow Transplantation - Blog Science Connections

Autologous Bone Marrow Transplantation for
Acute Myelogenous Leukemia:
24 CInselected Patients in First Remission
J.Y. Cahn, M. Flesch, E. Plouvier, B. Pignon, C. Behar, B. Audhuy,
A. Boilletot, P. Lute, A. Noir, and P. Heme
High-dose cytoreductive therapy followed by autologous bone marrow transplantation
(ABMT) has been used in various pilot studies as an alternative to
conventional therapy for acute myelogenous leukemia (AML) in first complete
remission (CR1). In our study, each AML patient was administered the same
induction regimen of daunorubicin, cytosine arabinoside, and 6-thioguanine
(DAT). Each patient lacking a sibling with identical human leukocytic antigens
(HLA) was included in the study if remission was obtained.
PATIENTS AND METHODS
Twenty-four patients with AML in CR1 were included in this pilot study: 14
adults with a median age of 29 years (range, 17-44 years) and 10 children with a
median age of 5.7 years (range, 2-14.5 years). Each patient achieved CR1
following chemotherapy with DAT. Consolidation chemotherapy was administered
with one course of daunorubicin and cytosine arabinoside. VPT6-213
(etoposide) or l-(2 chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNO) was added
after randomization. Only one patient received two courses of high-dose
cytosine arabinoside as consolidation regimen.
31